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P. CALMARZA6, M. HUND7 and F. V. ÁLVAREZ5, on behalf of the STEPS investigators#
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ABSTRACT
Objective A high ratio of soluble fms-like tyrosine
kinase-1 (sFlt-1) to placental growth factor (PlGF) has
been linked to pre-eclampsia (PE). We evaluated the
sFlt-1/PlGF ratio as a predictive marker for early-onset
PE in women at risk of PE.
Methods This prospective, Spanish, multicenter study
included pregnant women with a risk factor for PE,
including intrauterine growth restriction, PE, eclampsia
or hemolysis, elevated liver enzymes and low platelet
count syndrome in previous pregnancy, pregestational
diabetes or abnormal uterine artery Doppler. The primary
objective was to show that the sFlt-1/PlGF ratio at 20, 24
and 28 weeks’ gestation was predictive of early-onset PE
( 0 weeks). Serum sFlt-1 and PlGF were measured< 34 +
at 20, 24 and 28 weeks. Multivariate logistic regression
was used to develop a predictive model.
Results A total of 819 women were enrolled, of which
729 were suitable for analysis. Of these, 78 (10.7%)
women developed PE (24 early onset and 54 late onset).
Median sFlt-1/PlGF ratio at 20, 24 and 28 weeks was 6.3
(interquartile range (IQR), 4.1–9.3), 4.0 (IQR, 2.6–6.3)
and 3.3 (IQR, 2.0–5.9), respectively, for women who
did not develop PE (controls); 14.5 (IQR, 5.5–43.7),
18.4 (IQR, 8.2–57.9) and 51.9 (IQR, 11.5–145.6) for
women with early-onset PE; and 6.7 (IQR, 4.6–9.9),
4.7 (IQR, 2.8–7.2) and 6.0 (IQR, 3.8–10.5) for women
with late-onset PE. Compared with early-onset PE, the
sFlt-1/PlGF ratio was significantly lower in controls
(P < 0.001 at each timepoint) and in women with chronic
hypertension ( 0.001 at each timepoint), gestationalP <
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hypertension ( 0.001 at each timepoint) and late-onsetP <
PE (P < 0.001 at each timepoint). A prediction model
for early-onset PE was developed, which included the
sFlt-1/PlGF ratio plus mean arterial pressure, being parous
and previous PE, with areas under the receiver–operating
characteristics curves of 0.86 (95% CI, 0.77–0.95), 0.91
(95% CI, 0.85–0.97) and 0.93 (95% CI, 0.86–0.99) at
20, 24 and 28 weeks, respectively, and was superior to
models using the sFlt-1/PlGF ratio alone or uterine artery
mean pulsatility index.
Conclusions The sFlt-1/PlGF ratio can improve predic-
tion of early-onset PE for women at risk of this condition.
© 2016 The Authors. Ultrasound in Obstetrics & Gyne-
cology published by John Wiley & Sons Ltd on behalf of
the International Society of Ultrasound in Obstetrics and
Gynecology.
INTRODUCTION
Pre-eclampsia (PE) affects 2–5% of pregnancies1–5 and
can result in intrauterine growth restriction (IUGR), renal
or hepatic impairment, HELLP syndrome (hemolysis,
elevated liver enzyme levels and low platelet count),
eclampsia, and maternal and fetal mortality5–7. Early
and late manifestations of PE differ in time of onset
of symptoms, relative frequency, placental morphology,
genetic risk and risk of adverse outcomes8–13. Early-onset
PE is associated with a higher incidence of adverse
perinatal outcomes, including oligohydramnios, Apgar
score 7, stillbirth and early neonatal death, compared<
with late-onset PE14,15 . As early intervention is important
to improve maternal and fetal outcomes16 and the classical
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clinical markers of PE (hypertension and proteinuria) are
poorly predictive of those who will develop the condition,
markers of angiogenesis have been examined as aids to
PE prediction.
A key feature of PE is placental insufficiency.
Dysregulation of pro- and antiangiogenic factors is
thought to be causally linked to the condition7,17,18;
before and during PE, maternal serum concentrations of
antiangiogenic soluble fms-like tyrosine kinase-1 (sFlt-1)
are increased and levels of proangiogenic placental growth
factor (PlGF) are decreased19,20. A high sFlt-1/PlGF ratio
has been linked with PE and demonstrated before clinical
onset of the condition, and differences in sFlt-1 and PlGF
have been observed between early- and late-onset PE21–29.
The Elecsys® immunoassay sFlt-1/PlGF ratio is CE-IVD
(Conformit é Européenne–In Vitro Diagnostics) approved
as a diagnostic aid for PE with gestational age-specific
cut-off values, and as an aid in short-term prediction of
PE in women with suspected PE26,30,31. The Prediction of
Short-Term Outcome in Pregnant Women with Suspected
PE Study (PROGNOSIS) developed a cut-off-based PE
prediction model. Optimum sFlt-1/PlGF ratio cut-off
levels of 38 and≤ > 38 were identified to rule out and rule
in, respectively, PE, in women with singleton pregnancy
at 24 + 0 to 36 + 6 weeks’ gestation32 . However, the
predictive value of the sFlt-1/PlGF ratio has not been
examined specifically for early-onset PE.
This study, the Study of Early Pre-eclampsia in Spain
(STEPS), aimed to evaluate the sFlt-1/PlGF ratio at 20, 24
and 28 weeks as a predictive marker for early-onset PE in
women at risk of PE.
METHODS
Study design and participants
STEPS was a prospective, double-blind, multicenter (10
study sites in Spain) study, performed between October
2010 and March 2013, and enrolled pregnant women
at risk of PE. To be considered at risk of PE, women
had to meet one of the following inclusion criteria: PE,
eclampsia, HELLP syndrome or IUGR in a previous
pregnancy; pre-existing chronic hypertension without
proteinuria; gestational hypertension (new-onset hyper-
tension in pregnancy); pre-existing renal disease (kidney
transplantation or creatinine clearance < 60 mL/min);
pre-existing diabetes mellitus Type I (insulin depen-
dent); mean uterine artery Doppler pulsatility index
(UtA-PI) > 1.45 (at 19–20 weeks); thrombophilia
(antiphospholipid syndrome, protein C deficiency,
protein S deficiency, antithrombin deficiency, factor V
Leiden mutation); multiple pregnancy; age ≥ 40 years
and conceived with assisted reproductive technologies
(ART). Women with two or more of the following
risk factors were also included: nulliparity; body mass
index ≥ 35 kg/m2 ; diastolic blood pressure > 80 mmHg
at study inclusion; age 40 years; and family history≥
(mother or sister) of PE, eclampsia or HELLP syn-
drome. Women were excluded if they were both
hypertensive and had proteinuria or if major fetal
malformations/chromosome disorders were observed.
Women provided informed, signed consent. The
protocol was approved by applicable national/regional
independent ethics committees and institutional review
boards (Table S1). The study adhered to the Guidelines
for Good Clinical Practice.
The primary objective of the study was to demonstrate
that the sFlt-1/PlGF ratio was a predictive marker for
early-onset PE. Secondary objectives included evaluation
of sFlt-1/PlGF ratio as a predictor of late-onset PE and
the use of the sFlt-1/PlGF ratio for differentiation of
hypertension from PE.
Diagnostic criteria
For consistency, investigators used predefined diagnos-
tic criteria (Table 1) based on the Report of the
National High Blood Pressure Education Program Work-
ing Group on High Blood Pressure in Pregnancy33. PE
was defined as newly occurring hypertension (systolic
blood pressure 140 mmHg and/or diastolic blood pres-≥
sure ≥ 90 mmHg) with newly occurring proteinuria after
20 weeks. To be considered early onset, PE had to occur
before 34 + 0 weeks.
Data collection and visits
At gestational weeks 19–20 (Visit 1), 23–24 (Visit 2)
and 27–28 (Visit 3), participants underwent a blood
test to determine the sFlt-1/PlGF ratio, Doppler exam-
ination of the uterine arteries and assessment of blood
pressure (measured by validated automated devices), pro-
teinuria, PE status, hemoglobin, platelets and uric acid
levels. Postpartum, additional data were collected, includ-
ing blood pressure, type of delivery, Apgar score, weight of
placenta, neonatal outcomes (perinatal/fetal death, deliv-
ery 34 weeks, IUGR, placental abruption, respiratory<
distress syndrome, necrotizing enterocolitis, intraventricu-
lar hemorrhage) and maternal outcomes (maternal death,
pulmonary edema, acute renal failure, cerebral hemor-
rhage, cerebral thrombosis, disseminated intravascular
coagulation). Unplanned visits could be carried out in the
event of complications.
Serum samples (≥ 2 mL) were collected according to
a standard operating procedure and were analyzed at
the individual study sites. Results were checked for
consistency between study sites by central analysis at
Hospital Universitario Central de Asturias.
Maternal serum levels of sFlt-1 and PlGF were deter-
mined using the fully automated Elecsys sFlt-1 and
Elecsys PlGF assays on the cobas
®
e electrochemilu-
minescence immunoassay platform (Roche Diagnostics
GmbH, Mannheim, Germany) and the sFlt-1/PlGF ratio
was calculated27,30,31. The sFlt-1/PlGF ratio results were
concealed from both patients and carers to ensure that
they did not affect the clinical monitoring of patients.
Adverse events were recorded, although the study was
non-interventional.
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Table 1 Diagnostic criteria in Study of Early Pre-eclampsia in Spain (STEPS)
Diagnosis Criteria




Hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) diagnosed
before pregnancy or in first half of pregnancy (< 20weeks) and continued for >12 weeks after delivery
Proteinuria For determination of urinary protein using test strips, a value of 1 was not considered reliable for diagnosis+
of PE. Data were reconfirmed with protein test on 24-h urine ( 0.3g protein/24 h); in an emergency, if it≥
was not possible to determine protein in 24-h urine, protein determination was carried out on isolated
urine sample (≥30 mg protein/dL or protein/creatinine ratio≥ 30 mg protein/mmol creatinine)
Gestational
hypertension
New-onset hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg)
after 20 weeks of pregnancy, which resolved by 12 weeks postpartum
PE New-onset hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg)
and new-onset proteinuria after 20 weeks of pregnancy
Severe PE PE plus one or more of the following: systolic blood pressure≥ 160 mmHg and/or diastolic blood
pressure ≥ 110 mmHg (on two occasions at least 6 h apart); proteinuria (>5 g protein/24 h or test
strip ≥ +3 in two urine samples collected at random at least 4 h apart); impairment of renal function
(serum creatinine ≥ 1.2 mg/dL unless known to be elevated previously or oliguria< 500 mL/24 h);
pulmonary edema; impairment of hepatic function (elevated liver enzymes, epigastric pain or right upper
quadrant pain caused by distension of Glisson’s capsule); neurological symptoms (cerebral or visual
disturbances, severe headache); hematological disturbances (thrombocytopenia, hemolysis); IUGR
Eclampsia New-onset tonic–clonic convulsions in women with PE, not attributable to any other cause
Early- and late-onset PE Early onset: PE developing< 34 34+ ≥0 weeks; late onset: PE developing + 0 weeks
HELLP syndrome Increased ASAT ( 70 IU/L); decreased platelet count ( L); increased LDH (> < 100 000/μ > 600 IU/L)
IUGR Estimated fetal weight or abdominal circumference< 10th percentile (adjusted for gender/race in accordance
with tables normally used by study center). Presence of pathological process that inhibits expression of
normal intrinsic growth potential. Pathological process must be demonstrated at least once after
22 weeks, according to either oligohydramnios (amniotic fluid index< 10th percentile) or pathological
flow in umbilical artery (pulsatility index> 95th percentile)
SGA neonate Estimated fetal weight or abdominal circumference< 10th percentile (adjusted for gender/race in accordance
with tables normally used by study center); no pathological process
Preterm birth Delivery before end of 37 weeks (e.g. gestational age of 36+ 6 weeks would be recorded as 36 completed
weeks of pregnancy and baby would be defined as preterm)
ASAT, aspartate aminotransferase; HELLP, hemolysis, elevated liver enzymes and low platelet count; IUGR, intrauterine growth restriction;
LDH, lactate dehydrogenase; PE, pre-eclampsia; SGA, small-for-gestational-age.
Statistical analysis
To obtain 100 cases of PE, it was calculated that 800 preg-
nant women would need to be included in the study, based
on a presumed prevalence of PE of 12% (including both
singleton and multiple pregnancies). The sFlt-1/PlGF ratio
was log-transformed to correct for right skewness prior
to any calculation. Differences in means between inde-
pendent groups were assessed using analysis of variance
(ANOVA) or Student’s -test in the case of homogeneity oft
variances, and using generalized least squares in the case
of heteroscedasticity. Appropriateness of the methods
was assessed by evaluation of the plots of residuals.
To develop a predictive model of PE, multivariate
logistic regression was used considering maternal char-
acteristics, medical history and biomarkers as potential
predictors. The variables that were finally included in the
early-PE prediction model were selected according to the
results of a logistic regression model with L1 penalization
(‘lasso’ technique)34. The coefficients derived from the
multivariate analysis were used as weights in a nomogram
to predict early PE. Performances of the models were eval-
uated by receiver–operating characteristics (ROC) curves
and areas under the curve (AUC) with 95% CIs.
All statistical analyses were performed using R (version




Overall, 729 women were eligible for analysis, including
447 with singleton pregnancy and 282 with multiple
pregnancy (twin pregnancy, 276; triplet pregnancy,n =
n = 6). A total of 78 (10.7%) women developed PE
(singleton pregnancy, 42; multiple pregnancy,n = n = 36),
of which 24 were early-onset PE (singleton pregnancy,
n n= 14; multiple pregnancy, = 10) and 54 were late-onset
PE (singleton pregnancy, 28; multiple pregnancy,n =
n = 26) (Figure 1). The number of participants per study
site is reported in Table S2. Women who developed
early-onset PE had higher systolic and diastolic blood
pressures, mean arterial blood pressure (MAP) and lower
gestational age at delivery compared with the control
group (women who did not develop PE/hypertension
during the entire pregnancy) (Table 2).
sFlt-1, PlGF and sFlt-1/PlGF ratio measurements
In the control group, median sFlt-1/PlGF ratio remained
low ( 7) between 20 and 28 weeks’ gestation (Table 3).<
In women who developed early-onset PE, median
sFlt-1/PlGF ratio was already higher (14.5) at 20 weeks’
gestation and increased further to 18.4 at 24 weeks and
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Participants excluded*
(   90)n =
(S,   75; M,   15)n = n =
Participants who did not develop PE
(   651)n =
(S,   405; M,   246)n = n =
Participants who developed PE
(   78)n =




(   54)n =
(S,  n = 28;




(   24)n =
(S,  n = 14;
M,   10)n =
Participants
with IUGR
(   28)n =
(S,  n = 15;





(   35)n =
(S,  n = 22;




(   33)n =
(S,  n = 32;




(   555)n =
(S,   336;n =
M,  n = 219)
Participants enrolled
(   819)n =
(S,   522; M,   297)n = n =
Participants eligible for analysis
(   729)n =
(S,   447; M,   282)n = n =
Figure 1 Flowchart of participants in Study of Early Pre-eclampsia in Spain (STEPS). *Reasons for exclusion: inclusion criteria not met
(n = 4); signed consent given but did not start study (n= 28); miscarriage (n = 7); termination of pregnancy due to fetal malformations
( 13); placental abruption at 26 weeks (n = 8); lost to follow-up (n= n = 1); completed follow-up until 28 weeks but data could not be
retrieved because of delivery in another setting (n = 29). IUGR, intrauterine growth restriction; M, multiple pregnancy; PE, pre-eclampsia;
S, singleton pregnancy.









Age (years) 34.6 ± 5.3 35.6 ± 3.9 34.7 ± 0.7
Body mass index (kg/m2) 26.7 6.0 28.5 6.4 27.9 7.3± ± ±
Systolic blood pressure (mmHg) 119.1 ± 13.7 127.9 ± 13.5* 125.0 16.0*±
Diastolic blood pressure (mmHg) 73.7 ± 11.3 77.5 8.5* 77.7± ± 12.0*
Mean arterial pressure (mmHg) 88.9 ± 11.1 94.3 ± 8.1* 93.4 ± 12.2*
Multiple pregnancy 246 (37.8) 10 (41.7) 26 (48.1)
Gestational age at delivery (weeks) 37.5 ± 2.7 31.8 3.5* 36.6 1.4± ±
Birth weight of first infant (g) 2911 ± 721 ( 646) 1745 830 ( 584 ( 54)n = ± n = 22)* 2759 ± n =
Birth weight of second infant (g) 2303 ± 552 ( 243) 1807 378 ( 364 ( 26)n = ± n = 9)† 2285 ± n =
Birth weight of third infant (g) 1221 ± 689 ( 4) 1445 304 ( 2) — ( 0)n = ± n = n =
Nulliparous 272 (41.8) 15 (62.5) 31 (57.4)
Previous PE 101 (15.5) 9 (37.5)* 14 (25.9)
Family history of PE 23 (3.5) 1 (4.2) 5 (9.3)
Previous IUGR 55 (8.4) 3 (12.5) 5 (9.3)
Chronic hypertension 81 (12.4) 6 (25.0) 12 (22.2)
Gestational hypertension 4 (0.6) 0 (0) 3 (5.6)
Nephropathy 6 (0.9) 0 (0) 1 (1.9)
Diabetes mellitus Type 1 42 (6.5) 1 (4.2) 1 (1.9)
Thrombophilia 50 (7.7) 1 (4.2) 3 (5.6)
Conceived by assisted reproduction 93 (14.3) 5 (20.8) 11 (20.4)
Smoker at enrollment 80 (12.3) 1 (4.2) 3 (5.6)
Abnormal UtA Doppler 8 (1.2) 1 (4.2) 2 (3.7)
Data are given as mean 0.05, after adjustment by± SD or n P(%). PE groups compared with controls using Dunnett’s test: * < 0.001; †P<
Bonferroni correction. IUGR, intrauterine growth restriction; UtA, uterine artery.
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; : 373–382.50
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
Printed by [O
bstetrics and G
ynecology - 095.022.056.057 - /doi/epdf/10.1002/uog.17373] at [15/03/2021].
sFlt-1/PlGF STEPS 377
Table 3 Measurements of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF) and sFlt-1/PlGF ratio in maternal serum
at 20, 24 and 28weeks in women who developed early- or late-onset pre-eclampsia (PE) and in those who did not develop PE (controls)
Biomarker Controls Early-onset PE Late-onset PE
20 weeks
n 612 21 52
PlGF (pg/mL) 264.5 (172.0–403.6) 193.1 (68.0–262.4) 267.8 (151.5–414.0)
sFlt-1 (pg/mL) 1623.0 (1081.0–2531.0) 1972.0 (1331.0–3473.0) 1967.0 (1120.5–2903.8)
sFlt-1/PlGF ratio 6.3 (4.1–9.3) 14.5 (5.5–43.7) 6.7 (4.6–9.9)
24 weeks
n 580 20 52
PlGF (pg/mL) 424.5 (277.0–615.6) 168.9 (62.1–329.7) 415.0 (259.7–595.7)
sFlt-1 (pg/mL) 1725.0 (1123.5–2674.3) 3127.5 (1961.8–4202.5) 1882.5 (1134.5–3115.8)
sFlt-1/PlGF ratio 4.0 (2.6–6.3) 18.4 (8.2–57.9) 4.7 (2.8–7.2)
28 weeks
n 557 16 49
PlGF (pg/mL) 540.0 (339.0–821.5) 176.5 (67.2–278.6) 335.0 (263.0–485.9)
sFlt-1 (pg/mL) 1826.0 (1231.0–2766.0) 6370.0 (2385.3–8788.3) 2499.0 (1522.0–3681.0)
sFlt-1/PlGF ratio 3.3 (2.0–5.9) 51.9 (11.5–145.6) 6.0 (3.8–10.5)
Data are given as median (interquartile range) unless stated otherwise.
51.9 at 28 weeks. There was little change in the median
sFlt-1/PlGF ratio between 20 and 28 weeks in women
who developed late-onset PE, remaining low throughout
at < 7.
Mean sFlt-1 levels and PlGF levels were significantly
different between singleton and multiple pregnancies
at 20, 24 and 28 weeks (P = 0.001). However, the
mean sFlt-1/PlGF ratio was only significantly different
at 28 weeks’ gestation ( 0.001) (Table S3) and, atP=
all timepoints, the difference between median values in
singleton and multiple pregnancies was small.
sFlt-1/PlGF ratio: prediction of PE
Compared with control participants, the sFlt-1/PlGF ratio
was consistently significantly higher in women with
early-onset PE ( 0.001 at all timepoints) (Figure 2).P <
Women with early-onset PE also had significantly higher
sFlt-1/PlGF ratios at 20, 24 and 28 weeks relative to
women with chronic or gestational hypertension and
women with late-onset PE (Figure 3). Differences between
early-onset PE and control/hypertension/late-onset PE
became more pronounced as the pregnancy progressed.
Women with late-onset PE were not easily differenti-
ated from control participants by the sFlt-1/PlGF ratio
at 20 and 24 weeks (difference was non-significant at
20 (P P= 0.15) and 24 ( = 0.21) weeks, Figure 2). At
28 weeks, there was a statistically significant difference in
the sFlt-1/PlGF ratio between women with late-onset PE
and control participants (P < 0.001), although the numeri-
cal difference in the median ratio was small (2.7) (Table 3).
Development of a prediction model for early-onset PE
Prediction models for early-onset PE were developed,
which included variations of the following factors:
sFlt-1/PlGF ratio, PlGF, UtA-PI, MAP, being parous,
previous PE and use of ART. The AUC was optimal for a





























Figure 2 Soluble fms-like tyrosine kinase-1 (sFlt-1)/placental
growth factor (PlGF) ratio at 20, 24 and 28weeks in control group
of women who did not develop pre-eclampsia (PE; ) and in
those who developed early-onset ) or late-onset ) PE.
Comparison with controls: *P< 0.001; † 0.15; ‡ 0.21.P = P=
and previous PE (hereafter referred to as the ‘early-onset
PE prediction model’) (Figure S1) compared with models
that used the sFlt-1/PlGF ratio alone or UtA-PI alone
(Table 4). The accuracy of the prediction model was not
substantially improved by including ART or UtA-PI and
ART in the model. At 20 and 24 weeks, including these
two parameters in the model increased the AUC from
0.86 (95% CI, 0.77–0.95) to 0.87 (95% CI, 0.79–0.96),
and from 0.91 (95% CI, 0.85–0.97) to 0.92 (95% CI,
0.85–0.97), respectively. However, at 28 weeks, includ-
ing UtA-PI and ART in the model reduced the AUC from
0.93 (95% CI, 0.86–0.99) to 0.91 (95% CI, 0.82–0.99)
(Figure 4). A nomogram for prediction risk is presented in
Figures S2 and S3. The detection rate for early-onset PE
using different prediction models is reported in Table 5.
We also compared the performance of a standard
prediction model (maternal history, MAP and UtA-PI)
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Figure 3 Box-and-whisker plots of soluble fms-like tyrosine
kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio in control
women who did not develop pre-eclampsia (PE) and in those who
developed chronic hypertension (CH), gestational hypertension
(GH), late-onset PE or early-onset PE at: (a) 20 weeks, (b) 24 weeks
and (c) 28 weeks. †P < 0.001 in comparison with early-onset PE.
Boxes with internal lines represent median and interquartile range,
whiskers are 1.5 interquartile range and stars are outliers.×
with the same model but including the sFlt-1/PlGF
immunoassay ratio to estimate early-onset PE risk at
20, 24 and 28 weeks’ gestation. The addition of the
sFlt-1/PlGF immunoassay ratio substantially increased the
detection rate at all gestational ages studied (assuming a
false-positive rate of both 5% and 10%) (Table 6).
sFlt-1 and PlGF as single biomarkers: development
of PE
Women with early-onset PE had lower PlGF (P < 0.001
at 20, 24 and 28 weeks) and higher sFlt-1 (P = 0.018,
P P< 0.001 and < 0.001 at 20, 24 and 28 weeks,
respectively) compared with those who did not develop
early-onset PE (women who developed late-onset PE
and those who did not develop any PE combined)
(Figure S4).
A comparison of prediction models that included the
sFlt-1/PlGF ratio with models that used sFlt-1 or PlGF
alone was performed by evaluating their respective AUCs
and Akaike information criterion (AIC), which measures
goodness of fit35. The AUC for prediction models that
included the sFlt-1/PlGF ratio (0.86–0.87, 0.91–0.92 and
0.91–0.93 at 20, 24 and 28 weeks’ gestation, respectively)
was greater than that of models that used single
biomarkers (0.81–0.83, 0.88–0.90 and 0.88–0.91 for
sFlt-1 and 0.79–0.83, 0.85–0.89 and 0.86–0.89 for PlGF
at 20, 24 and 28 weeks’ gestation, respectively) (Table S4).
Data consistency
No inconsistencies were found between site and central
testing (data not shown).
DISCUSSION
Substantial evidence supports the use of the sFlt-1/PlGF
ratio in PE diagnosis and prediction20,21,23,27,36–40.
However, differences between early- and late-onset
PE suggest different etiologies; thus, different ‘rules’
for the sFlt-1/PlGF ratio could be applied. In a
study of 257 women with suspected PE, the optimal
sFlt-1/PlGF ratio cut-off to diagnose PE < 34 weeks’ and
≥ 34 weeks’ gestation was 23 (92.0% sensitivity, 81.1%
specificity) and 45 (83.7% sensitivity, 72.6% specificity),
respectively41. In PROGNOSIS, a sFlt-1/PlGF ratio cut-off
≤ 38 ruled out PE within 1 week in women with suspected
PE and singleton pregnancy at 24 + 0 to 36 +6 weeks’
gestation32 . PROGNOSIS had a higher prevalence of PE
compared with our study (19% 11%, respectively),vs
possibly due to the fact that PROGNOSIS enrolled women
with suspicion of PE, while we enrolled women with a
moderate or high risk of developing PE. The prevalence
of PE in our study falls between the estimated ranges for
women with moderate or high risk for PE (5.29–6.19%
and 16.09–19.49%, respectively)42.
In STEPS, the sFlt-1/PlGF ratio was significantly
different between women who did not develop PE and
those who did. The combination of the sFlt-1/PlGF ratio
with other clinical measures produced a predictive model
with considerably increased specificity and sensitivity
compared with using UtA-PI or sFlt-1/PlGF ratio alone.
We also evaluated how the models used to estimate
early-onset PE risk would perform when using the
single biomarkers, instead of the sFlt-1/PlGF ratio. Based
on both AUC and AIC, models with the sFlt-1/PlGF
ratio demonstrated consistently the highest predictive
performance. Using our early-onset PE prediction model
(sFlt-1/PlGF ratio, MAP, being parous, previous PE),
early-onset PE could be predicted from 20 weeks onward,
with an AUC of 0.86 and 60% sensitivity for a
false-positive rate of 10%. A previous model developed
without serum biomarkers, which used a history of
diabetes, hypertension and MAP, reported an AUC of
0.83 with 55% sensitivity for a false-positive rate of 10%
(these were not high-risk women)43.
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Table 4 Prediction of early-onset pre-eclampsia (PE) at 20, 24 and
28 weeks using different individual parameters and early-onset PE
prediction model
Prediction parameter AUC (95% CI)
20 weeks





sFlt-1/PlGF ratio 0.77 (0.65–0.89)
24 weeks





sFlt-1/PlGF ratio 0.86 (0.76–0.96)
28 weeks





sFlt-1/PlGF ratio 0.89 (0.79–0.98)
Early-onset PE prediction model includes soluble fms-like tyrosine
kinase 1(sFlt-1)/placental growth factor (PlGF) ratio, mean arterial
pressure (MAP), being parous and previous PE. AUC, area under
the receiver–operating characteristics curve; UtA-PI, uterine artery
pulsatility index.
Other studies have included sFlt-1 and PlGF in
their models. An observational study of women at
high risk of PE developed a prediction model for
early-onset PE using sFlt-1 at 28 + 0 to 31 +6 weeks’
gestation, which had an AUC of 0.85 (67% sensitivity,
96% specificity)44. A model including gestational age,
UtA-PI and sFlt-1/PlGF ratio showed an association with
perinatal complications with an AUC of 0.89 (64%
sensitivity, 95% specificity)45. Another model combined
PlGF with maternal characteristics, obstetric history and
UtA-PI to predict early-onset PE in the first trimester with
an AUC of 0.9446 . Although an abnormal UtA-PI was
associated with the development of PE in our study, it was
not included in our model since it did not substantially
improve PE prediction. From a practical perspective, the
UtA can be difficult to locate in the first trimester and
the International Society of Ultrasound in Obstetrics and
Gynecology does not include UtA Doppler as part of
the routine first-trimester fetal ultrasound examination47.
Other studies have also not included UtA-PI in their
models48,49 .
A recent study demonstrated that a prospective
screening model at 19–24 weeks’ gestation, involving
maternal factors, UtA-PI, MAP and PlGF, was superior
to screening by maternal factors alone. The performance
of the model was inversely related to the gestational
age at which delivery became necessary; detection rates
(false-positive rate of 10%) for PE 32 weeks, between<
32 0 and 36 37 weeks were 99%, 85%+ + ≥6 weeks, and
































































Figure 4 Receiver–operating characteristcs curves for prediction of
early-onset pre-eclampsia (PE) using different models at
20 weeks (a), 24 weeks (b) and 28 weeks (c). Tables S4 and 5
present numerical values for areas under curves. Early-onset PE
prediction model ) includes soluble fms-like tyrosine kinase-1
(sFlt-1)/placental growth factor (PlGF) ratio, mean arterial pressure
(MAP), being parous and previous PE. ART, assisted reproductive
technologies; UtA-PI, uterine artery pulsatility index.
, sFlt-1/PlGF ratio, MAP, being parous, previous PE, ART.
, sFlt-1/PlGF ratio, MAP, being parous, previous PE, UtA-PI,
ART.
, MAP, being parous, previous PE, ART, PlGF.
, MAP, being parous, previous PE, UtA-PI, ART, PlGF.
PlGF and sFlt-1 separately; it did not assess the sFlt-1/PlGF
ratio50 . Of note, the study defined early-onset PE as
requiring delivery before 32 weeks’ gestation, rather than
before 34 weeks. A related study showed that a two-stage
screening model, in which UtA-PI and PlGF measurements
were reserved for at-risk individuals, achieved similar
detection rates for preterm PE ( 37 weeks’ gestation),<
compared with screening the whole population by
maternal factors, MAP, UtA-PI and PlGF51.
Various guidelines recommend PE screening based on
maternal history52–54. However, the addition of MAP,
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Table 5 Prediction rates of early-onset pre-eclampsia (PE) using different models at 20, 24 and 28weeks
Detection rate (%)
Prediction model FPR = 5% FPR = 10%
20 weeks
Early-onset PE prediction model 45 60
sFlt-1/PlGF ratio, MAP, being parous, previous PE, UtA-PI and ART 50 60
sFlt-1/PlGF ratio, MAP, being parous, previous PE and ART 55 60
MAP, being parous, previous PE, UtA-PI, ART and PlGF 35 55
MAP, being parous, previous PE, ART and PlGF 45 45
24 weeks
Early-onset PE prediction model 60 70
sFlt-1/PlGF ratio, MAP, being parous, previous PE, UtA-PI and ART 72 78
sFlt-1/PlGF ratio, MAP, being parous, previous PE and ART 60 70
MAP, being parous, previous PE, UtA-PI, ART and PlGF 56 67
MAP, being parous, previous PE, ART and PlGF 56 67
28 weeks
Early-onset PE prediction model 81 81
sFlt-1/PlGF ratio, MAP, being parous, previous PE, UtA-PI and ART 73 80
sFlt-1/PlGF ratio, MAP, being parous, previous PE and ART 81 81
MAP, being parous, previous PE, UtA-PI, ART and PlGF 53 53
MAP, being parous, previous PE, ART and PlGF 53 53
Early-onset PE prediction model includes soluble fms-like tyrosine kinase 1(sFlt-1)/placental growth factor (PlGF) ratio, mean arterial
pressure (MAP), being parous and previous PE. Areas under receiver–operating chracteristics curves for each model are provided in
Table S4. ART, assisted reproductive technologies; FPR, false-positive rate; UtA-PI, uterine artery pulsatility index.
Table 6 Performance of standard prediction model and same model plus soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor
(PlGF) ratio to estimate risk of early-onset pre-eclampsia at 20, 24 and 28weeks
Detection rate (%)
Prediction model AUC (95% CI) FPR= 5% FPR = 10%
20 weeks
Standard prediction model (maternal history, MAP, UtA-PI) 0.81 (0.71–0.89) 17 48
Standard prediction model plus sFlt-1/PlGF ratio 0.91 (0.85–0.97) 60 70
24 weeks
Standard prediction model (maternal history, MAP, UtA-PI) 0.87 (0.79–0.94) 40 60
Standard prediction model plus sFlt-1/PlGF ratio 0.95 (0.90–0.99) 72 83
28 weeks
Standard prediction model (maternal history, MAP, UtA-PI) 0.89 (0.83–0.95) 42 58
Standard prediction model plus sFlt-1/PlGF ratio 0.95 (0.90–1.00) 80 80
AUC, area under receiver–operating characteristics curve; FPR, false-positive rate; MAP, mean arterial pressure; UtA-PI, uterine artery
pulsatility index.
UtA-PI and angiogenic serum markers to the assessment
of maternal history has been shown to increase the PE
detection rate between 12 and 36 weeks’ gestation55–58. In
STEPS, the addition of the sFlt-1/PlGF ratio increased the
detection rate at all gestational ages studied, supporting
the inclusion of the sFlt-1/PlGF ratio in the risk estimation
of early-onset PE.
The prospective, longitudinal design and large cohort
in our study provided a robust dataset and the angiogenic
marker results were hidden from the investigators to avoid
bias in the diagnosis of outcomes. However, despite the
large sample size, there were relatively small numbers of
women in the early-onset PE group and the results of
this study, which included women at risk of developing
PE, cannot be applied to a low-risk population, i.e. in
screening for PE. The data were validated using the
Elecsys immunoassay sFlt-1/PlGF ratio and the predictive
value may differ when other assays are used. The
developed prediction model for early-onset PE has to
be validated in an independent prospective study cohort
in a comparable target population, and interventional
studies are required to confirm the clinical utility of the
results.
STEPS provides further evidence that the addition of
the sFlt-1/PlGF ratio to clinical protocols for women
at risk of PE improves prediction of early-onset PE
in the second trimester. This complements the findings
of PROGNOSIS, which showed that, in women with
signs and/or symptoms of PE and a sFlt-1/PlGF ratio
above 38, the positive predictive value for PE within
the following 4 weeks was 36.7%32. In STEPS, women
who developed early-onset PE had a median sFlt-1/PlGF
ratio at 28 weeks’ gestation of 51.9, indicating that
these women had an increased risk of developing PE
in the following 4 weeks before 34 0 weeks’ gestation.+
Better prediction of PE could facilitate targeting of
monitoring and therapeutic procedures towards at-risk
women and allow better utilization of healthcare
resources.
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Table S4 Performance of different prediction models using soluble fms-like tyrosine kinase-1 (sFlt-1)/placental
growth factor (PlGF) ratio, sFlt-1 or PlGF to estimate risk of early-onset pre-eclampsia (PE) at 20, 24 and
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Figure S1 Formulae used in prediction model for early-onset pre-eclampsia (PE). MAP, mean arterial pressure.
Figure S2 Nomogram for estimation of risk of early-onset pre-eclampsia (PE) at 24 weeks. To calculate
probability of early-onset PE for a given patient, the value for each predictor is obtained by drawing a vertical
line straight upward from that factor to the ‘points’ axis. The points are then summed and the sum located on
the total points nomogram, and the probability of early-onset PE is located by drawing a vertical line
downward to the ‘risk of PE’ line. MAP, mean arterial pressure; PlGF, placental growth factor; sFlt-1, soluble
fms-like tyrosine kinase-1.
Figure S3 Worked example of the use of the nomogram for estimation of risk of early-onset pre-eclampsia
(PE) at 24 weeks. To calculate visually risk of early-onset PE in a parous patient with previous PE at 24 weeks,
with mean arterial pressure (MAP) of 100 mmHg and soluble fms-like tyrosine kinas-1 (sFlt-1)/placental
growth factor (PlGF) ratio of 50, points are assigned for each item by plotting a line from the item to the
points line. Being parous equates to 0 points; 100 mmHg MAP corresponds to 9 points; previous PE equates to
38 points; and sFlt-1/PlGF ratio of 50 (In = 3.91) gives 62 points. Total number of points is 109; drawing a
vertical line downward from total points axis to ‘risk of PE’ line, the risk is estimated at approximately 80%.
Figure S4 Placental growth factor (PlGF) (a) and soluble fms-like tyrosine kinase-1 (sFlt-1) (b) at 20, 24 and
28 weeks in women who developed early-onset pre-eclampsia (PE) and in control participants who did not
develop PE.
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